UBS Group
TVTX icon

UBS Group’s Travere Therapeutics TVTX Stock Holding History

UBS Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.5M Buy
856,757
+434,138
+103% +$13M ﹤0.01% 2331
2025
Q4 		$16.1M Sell
422,619
-70,454
-14% -$2.29M ﹤0.01% 2786
2025
Q3 		$11.8M Sell
493,073
-157,208
-24% -$2.96M ﹤0.01% 3115
2025
Q2 		$9.62M Sell
650,281
-54,712
-8% -$907K ﹤0.01% 3115
2025
Q1 		$12.6M Sell
704,993
-4,364
-0.6% -$88.6K ﹤0.01% 2809
2024
Q4 		$12.4M Buy
709,357
+383,122
+117% +$6.78M ﹤0.01% 2831
2024
Q3 		$4.56M Buy
326,235
+194,729
+148% +$2.03M ﹤0.01% 3173
2024
Q2 		$1.08M Sell
131,506
-241,105
-65% -$1.62M ﹤0.01% 4348
2024
Q1 		$2.87M Buy
372,611
+196,131
+111% +$1.65M ﹤0.01% 3573
2023
Q4 		$1.59M Buy
176,480
+103,295
+141% +$752K ﹤0.01% 4051
2023
Q3 		$654K Sell
73,185
-62,137
-46% -$877K ﹤0.01% 4448
2023
Q2 		$2.08M Buy
135,322
+9,537
+8% +$173K ﹤0.01% 3480
2023
Q1 		$2.83M Sell
125,785
-84,329
-40% -$1.79M ﹤0.01% 3056
2022
Q4 		$4.42M Buy
210,114
+167,838
+397% +$3.56M ﹤0.01% 2622
2022
Q3 		$1.04M Sell
42,276
-59,490
-58% -$1.54M ﹤0.01% 3724
2022
Q2 		$2.47M Sell
101,766
-51,550
-34% -$1.3M ﹤0.01% 2970
2022
Q1 		$3.95M Sell
153,316
-10,890
-7% -$289K ﹤0.01% 2772
2021
Q4 		$5.1M Buy
164,206
+163,607
+27,313% +$4.61M ﹤0.01% 2793
2021
Q3 		$14K Sell
599
-13,725
-96% -$252K ﹤0.01% 7598
2021
Q2 		$209K Sell
14,324
-35,958
-72% -$709K ﹤0.01% 5305
2021
Q1 		$1.26M Buy
50,282
+48,860
+3,436% +$1.35M ﹤0.01% 4020
2020
Q4 		$38K Buy
+1,422
New +$33.2K ﹤0.01% 6430
2020
Q3 		– Sell
-237
Closed -$5K – 8419
2020
Q2 		$5K Sell
237
-10,388
-98% -$165K ﹤0.01% 7388
2020
Q1 		$155K Sell
10,625
-22,998
-68% -$346K ﹤0.01% 4918
2019
Q4 		$477K Sell
33,623
-129,557
-79% -$1.65M ﹤0.01% 4879
2019
Q3 		$1.89M Buy
163,180
+140,411
+617% +$2.32M ﹤0.01% 3342
2019
Q2 		$458K Buy
22,769
+22,418
+6,387% +$443K ﹤0.01% 4356
2019
Q1 		$8K Sell
351
-40,050
-99% -$885K ﹤0.01% 6955
2018
Q4 		$914K Buy
40,401
+34,023
+533% +$846K ﹤0.01% 3755
2018
Q3 		$183K Buy
6,378
+6,073
+1,991% +$174K ﹤0.01% 5137
2018
Q2 		$8K Sell
305
-36,752
-99% -$979K ﹤0.01% 7276
2018
Q1 		$829K Buy
37,057
+35,874
+3,032% +$854K ﹤0.01% 3866
2017
Q4 		$25K Sell
1,183
-10,498
-90% -$240K ﹤0.01% 6384
2017
Q3 		$290K Buy
11,681
+10,599
+980% +$233K ﹤0.01% 4595
2017
Q2 		$21K Buy
1,082
+582
+116% +$10.6K ﹤0.01% 6263
2017
Q1 		$9K Sell
500
-23,436
-98% -$458K ﹤0.01% 6687
2016
Q4 		$453K Buy
23,936
+22,226
+1,300% +$455K ﹤0.01% 4202
2016
Q3 		$38K Sell
1,710
-38,807
-96% -$739K ﹤0.01% 5734
2016
Q2 		$721K Buy
40,517
+39,717
+4,965% +$643K ﹤0.01% 3631
2016
Q1 		$11K Sell
800
-64,964
-99% -$986K ﹤0.01% 6609
2015
Q4 		$1.27M Buy
65,764
+64,964
+8,121% +$1.3M ﹤0.01% 3212
2015
Q3 		$16K Sell
800
-463
-37% -$13.7K ﹤0.01% 6914
2015
Q2 		$42K Buy
+1,263
New +$34.6K ﹤0.01% 6152

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group's TVTX Position: Q1 2026 in Review

UBS Group increased its Travere Therapeutics (TVTX) stake by 103% in Q1 2026, buying an estimated $13M and bringing the position to 856,757 shares worth $25.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

UBS Group first reported a position in TVTX in Q2 2015 and has held it in 43 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • UBS Group held 856,757 shares of Travere Therapeutics worth $25.5M as of Q1 2026.
  • UBS Group bought 434,138 Travere Therapeutics shares in Q1 2026, an estimated $13M.
  • Travere Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2331 holding.
  • UBS Group first reported a position in Travere Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.